Education
About Us
Working with TipRanks
Follow Us
Starpharma Holdings Limited (AU:SPL)
ASX:SPL
SPL Stock Chart & Stats
AU$0.38
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.38
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.53
Previous CloseN/A
Volume337.59K
Average Volume (3M)724.95K
Market Cap
AU$193.16M
Enterprise ValueAU$175.70M
Total Cash (Recent Filing)AU$18.25M
Total Debt (Recent Filing)AU$790.00K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding419,915,680
10 Day Avg. Volume366,126
30 Day Avg. Volume724,950
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)1.93
Price to Sales (P/S)7.47
P/FCF Ratio-5.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$15.80M
Bulls Say, Bears Say
Bulls Say
Proprietary Dendrimer PlatformStarpharma's proprietary dendrimer platform is a durable competitive asset: it creates technical barriers to entry, supports multiple productisation paths (therapeutics, delivery, materials), and enables recurring partner engagements. Over 2-6 months this underpins licensing optionality and long-term revenue potential as partners commercialise dendrimer-enabled products.
Diversified Partnership Revenue StreamsThe company's business model generates revenue from licensing, milestones, royalties and service/material sales. This mix reduces binary clinical risk exposure because partner-funded milestones and downstream royalties can produce multi-year, scalable income streams, improving resilience versus a single-product dependency.
Solid Revenue GrowthReported revenue growth of +18.13% indicates growing adoption of Starpharma's platform and services. Sustainable top-line expansion provides a foundation to scale fixed-cost absorption, improve operating leverage, and potentially support margin recovery as recurring partnership revenues and product supply scale over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows mean Starpharma must rely on external funding or partner milestones to sustain operations. This weak cash conversion limits reinvestment capacity, increases dilution or financing risk, and constrains the company's ability to independently scale R&D or commercialisation without clear near-term cash inflection events.
Persistent Unprofitability And Weak MarginsOngoing negative EBIT and net margins show the business has not yet converted revenue into sustainable profits. Continued unprofitability compresses internal funding for development and commercialization, keeps dependency on external capital, and risks prolonged shareholder dilution until partner royalties or product sales materially improve margins.
Negative Return On EquityDespite a conservative balance sheet with low leverage, the negative ROE indicates capital is not generating adequate returns. This signals inefficiency in deploying equity for profitable growth; unless commercial products or partner royalties ramp, shareholders may face extended periods without positive returns on invested capital.
Starpharma Holdings Limited News
SPL FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.08 and its highest was AU$0.53 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is AU$193.16M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 177 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 419,915,680 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in AU:SPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:SPL Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $82.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
355.55%
12-Months-Change
Fundamentals
Return on Equity
-41.51%
Trailing 12-Months
Asset Growth
-32.24%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited (SPL) is an Australian biotechnology company focused on the development of innovative drug delivery systems and new therapeutic products. The company specializes in dendrimer technology, which allows for enhanced delivery of drugs and provides unique solutions in various sectors, including pharmaceuticals and personal care. SPL's core products include its proprietary VivaGel, a dendrimer-based gel for the treatment of bacterial vaginosis and prevention of sexually transmitted infections, as well as collaborations in the development of oncology drugs.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Island Pharmaceuticals Ltd
―
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
Options Prices
Currently, No data available
---